SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Bought by Bruderman Asset Management LLC

Bruderman Asset Management LLC raised its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 11.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,264 shares of the exchange traded fund’s stock after acquiring an additional 5,218 shares during the quarter. SPDR S&P Biotech ETF makes up 1.1% of Bruderman Asset Management LLC’s investment portfolio, making the stock its 29th largest position. Bruderman Asset Management LLC owned approximately 0.09% of SPDR S&P Biotech ETF worth $4,689,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Morgan Stanley raised its stake in shares of SPDR S&P Biotech ETF by 23.8% during the second quarter. Morgan Stanley now owns 9,568,839 shares of the exchange traded fund’s stock valued at $910,858,000 after purchasing an additional 1,840,100 shares during the period. JPMorgan Chase & Co. increased its stake in shares of SPDR S&P Biotech ETF by 64.5% in the first quarter. JPMorgan Chase & Co. now owns 1,462,600 shares of the exchange traded fund’s stock worth $128,314,000 after buying an additional 573,431 shares during the last quarter. Assetmark Inc. increased its stake in shares of SPDR S&P Biotech ETF by 271,147.4% in the second quarter. Assetmark Inc. now owns 1,264,013 shares of the exchange traded fund’s stock worth $120,321,000 after buying an additional 1,263,547 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of SPDR S&P Biotech ETF by 159.3% in the second quarter. SG Americas Securities LLC now owns 977,702 shares of the exchange traded fund’s stock worth $93,067,000 after buying an additional 600,603 shares during the last quarter. Finally, CI Investments Inc. bought a new stake in shares of SPDR S&P Biotech ETF in the first quarter worth $52,366,000.

Shares of NYSEARCA:XBI traded down $0.95 during midday trading on Monday, reaching $89.50. The company had a trading volume of 6,874,853 shares, compared to its average volume of 4,459,501. SPDR S&P Biotech ETF has a one year low of $78.46 and a one year high of $101.55.

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 26th. Investors of record on Monday, September 24th were paid a $0.0726 dividend. This represents a $0.29 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date was Friday, September 21st. This is a positive change from SPDR S&P Biotech ETF’s previous quarterly dividend of $0.06.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also: What strategies should day traders use to execute a trade?

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply